The receptor tyrosine kinase HER2 enhances tumor metastasis; however, its role in homing to metastatic organs is poorly understood. The chemokine receptor CXCR4 has recently been shown to mediate the movement of malignant cancer cells to specific organs. Here, we show that HER2 enhances the expression of CXCR4, which is required for HER2-mediated invasion in vitro and lung metastasis in vivo. HER2 also inhibits ligand-induced CXCR4 degradation. Finally, a significant correlation between HER2 and CXCR4 expression was observed in human breast tumor tissues, and CXCR4 expression correlated with a poor overall survival rate in patients with breast cancer. These results provide a plausible mechanism for HER2-mediated breast tumor metastasis and establish a functional link between HER2 and CXCR4 signaling pathways.
Figure 1. HER2 enhances the chemokine receptor CXCR4 expression
A: MDA-MB-435 cells and their HER2 stable transfectants were stained for the CXCR4 antibody (MAB 172; R&D) and analyzed using FACS. The upper panel shows CXCR4 expression in HER2/435 (blue) and 435/neo (red) vector control cell lines compared with an isotype control preparation (green). The lower panel shows similar staining for NIH 3T3 (red) and its HER2 transfectant (blue). B: HER2 enhances CXCR4 expression demonstrated by immunofluorescent staining. 435/neo and 435/HER2 cells were stained with anti-HER2 (green) and anti-CXCR4 (red) antibodies and examined under a confocal microscope (Olympus). C: Herceptin reduces CXCR4 level in HER2-overexpressing cells. 435/HER2, 435/neo, and BT-474 cells were treated with Herceptin 15 g/ml for 36 hr (red); BT-474 cells were treated with HER2 siRNA and subjected for FACS analysis. D: Western blot supporting CXCR4 (top panel) expression and HER2 status (second panel) of MDA-MB-435 cells, two HER2 stable transfectants, and BT-474 cells used in FACS. The human actin was used as a loading control for the Western blot (bottom). Band intensities were quantitated, and the relative ratios of CXCR4 intensity among the different treatments were shown below the first lane. E: Analysis of CXCR4 mRNA expression. 435/neo cells and two 435/HER2 stable transfectants were harvested, and total RNA was prepared for Northern blotting using human CXCR4 (top) cDNA probes. The human GAPDH and total 18S and 28S ribosomal RNA were used as a loading control (second and bottom panel).
CXCR4 is one of the best-characterized chemokine receptors.
independent HER2 stable transfectants of MDA-MB-435 breast cancer cells by Western blot ( Figure 1D , left panel) and also In addition to inducing leukocyte trafficking (Hernandez et al., 2003) , CXCR4 is essential for B cell lymphopoiesis and myeloobserved in the NIH 3T3 cell and its HER2 stable transfectant ( Figure 1A ). The increase in CXCR4 expression by HER2 was poiesis (Nagasawa et al., 1996) , gastrointestinal tract vascularization (Tachibana et al., 1998) , neuronal and germ cell migration further supported by fluorescence confocal microscopy ( Figure  1B ). The 435/HER2 cells expressed much higher levels of (Knaut et al., 2003; Kunwar and Lehmann, 2003; Zou et al., 1998) , and HIV invasion of host cells (Connor et al., 1997; Scar- CXCR4 than did the vector control cells (435/neo) (red) ( Figure  1B) ; the HER2 status was confirmed using an anti-HER2 antilatti et al., 1997). Moreover, CXCR4 and its ligand, SDF-1␣, play an important role in the targeted metastasis of breast cancer body staining (green). To further examine whether HER2 is required for the enhanced CXCR4 expression in HER2-overex- (Liotta, 2001; Muller et al., 2001 ). Chemokines such as SDF-1␣ are released in high amounts by certain organs, such as lung, pressing cancer cells, we used a HER2-specific monoclonal antibody, Herceptin, that is known to downregulate HER2 (Carbone, and liver. Malignant breast cancer cells, which express the chemokine receptor CXCR4, invade the extracellular matrix ter et al., 1992; Klos et al., 2003; Pietras et al., 1998) and found that Herceptin decreases the CXCR4 expression in 435/HER2 and circulate in the blood and lymphatic vessels. The attraction between SDF-1␣ and CXCR4 causes breast cancer cells to cells, compared to control IgG. However, Herceptin does not affect the CXCR4 expression in 435/neo cells ( Figure 1C ). Downleave the circulation and migrate into organs with large amounts of chemokines, where the cancer cells proliferate, induce angioregulating CXCR4 by Herceptin was also observed in endogenous HER2 overexpressing BT-474 cells by FACS ( Figure 1C ) genesis, and form metastatic tumors. CXCR4 is also involved in the metastasis of prostate cancer to the bone marrow (Taichand Western blot ( Figure 1D , middle panel). Similar results were also observed using RNA interference to deplete HER2 expresman et al., 2002) and of colon cancer to the liver (Zeelenberg et al., 2003) .
sion (Figures 1C and 1D, right panel) . Therefore, these results indicate that HER2 is able to increase the expression of the In an attempt to understand how HER2 overexpression increases metastatic potential and, in particular, homing to its chemokine receptor CXCR4. We further investigated the molecular mechanism behind metastatic organs, which cause the majority of cancer patient deaths (Hortobagyi, 1998; Landis et al., 1999; Slamon et al., HER2-induced CXCR4 expression. HER2 does not enhance CXCR4 mRNA level, as shown by Northern blot analysis ( Figure  2001 ), we found that HER2 enhances the expression of CXCR4. CXCR4 expression was also shown to predict poor patient sur-1E). Therefore, it is likely that HER2 regulates CXCR4 at the protein level. We used metabolic labeling assays to detect the vival. Furthermore, we found that CXCR4 is required for HER2-protein synthesis and degradation of CXCR4. Pulse-labeling mediated metastatic potential in vitro and in vivo. Our data studies demonstrated that HER2 increases the protein synthesis establish a molecular mechanism whereby HER2-overexpressrate of the CXCR4 receptor, which is 2.5-fold faster than the ing cancer cells home to specific organs and provide crucial control before the first 2 hr ( Figure 1F ). Pulse-chase experiments evidence of a functional link between the HER2 and CXCR4
( Figure 1G ) indicated that HER2 only slightly lowers the basal signaling pathways.
protein degradation rate of CXCR4 (please note that this is different from the ligand-dependent degradation that is deResults scribed in Figure 3B ); however, considering the standard deviation from three independent experiments, there is no statistical HER2 enhances the chemokine receptor CXCR-4 expression difference between them. Thus, the increased CXCR4 protein level in the HER2-expressing cells is primarily caused by enIt is well known that HER2 enhances cancer invasion and lung metastasis (Tan et al., 1997; Yarden and Sliwkowski, 2001 ; Yu hanced translational rate ( Figure 1F ) and is less influenced by the basal degradation rate ( Figure 1G ). Since HER2 can activate and , and the chemokine receptor CXCR4 is involved in the metastasis of breast cancer to the lung (Muller et Akt (Zhou et al., 2000) , which is known to stimulate the mammalian target of rapamycin (mTOR) to enhance protein synthesis al., 2001). We hypothesized that CXCR4 plays a role in HER2-mediated metastasis. To test this hypothesis, we examined (Gingras et al., 2001) , we next examined whether the enhancement of CXCR4 protein synthesis by HER2 might occur through CXCR4 expression by fluorescence-activated cell sorting (FACS) analysis and found that CXCR4 expression was 2.8 Ϯ 0.6-fold the PI-3K/Akt/mTOR pathway. If mTOR is involved in the HER2-enhanced CXCR4 translation, blockage of the mTOR activity higher in the HER2 transfectants of MDA-MB-435 breast cancer cells (435/HER2) than that in the vector control cells (435/neo) and its upstream signals such as PI-3 kinase and HER2 tyrosine kinase should inhibit HER2-induced CXCR4 expression. Con-( Figure 1A ). In addition, this phenomenon was supported in two A: Invasive assays were performed using the Boyden Chamber assay coated with Matrigel, which mimics basement membrane composition, and SDF-1␣, a ligand for CXCR4, as a chemoattractive agent in the lower chamber. For the blocking assay, either CXCR4 blocking antibody (1-10 g/ml) or Herceptin (5 g/ml; 15 g/ml) was added into cell culture. Cells were counted in triplicate wells and in five identical experiments. B-E: Quantification of invasion assays. *p Ͻ 0.05. F: The migration assay was performed in a manner similar to the invasive assay, except in the absence of Matrigel. Quantification of migration is shown. *p Ͻ 0.05. G and H: HER2 significantly enhances adhesion to endothelial cells. Cell-to-cell adhesion was quantified using a fluorescent plate reader. Data are presented as mean raw fluorescent counts per well of the mean. *p Ͻ 0.05. sistent with this notion, treatment of different inhibitors, includSimilar results were observed for 3T3 and 3T3/HER2 cells (Figures 2A and 2C) and endogenous HER2-overexpressing BT-474 ing the inhibitors for HER2 tyrosine kinase (AG825), PI-3 kinase (Wortmannin and LY294002), and mTOR (rapamycin) indeed cells ( Figure 2D ). Since Herceptin downregulated CXCR4 expression ( Figures 1C and 1D ), the SDF-1␣-induced in vitro invasive inhibited CXCR4 expression in 435/HER2 cells. The phosphorylation of tyrosine residue of HER2, phosphorylation of Akt at activity was also inhibited by Herceptin in two HER2-overexpressing cell lines, 435/HER2 and BT-474 ( Figures 2D and 2E ). residue serine 473, and phosphorylation of p70S6k at residue threonine 389 were also examined as controls for proper effects Thus, these results indicate that upregulation of CXCR4 by HER2 is required for in vitro invasion induced by SDF-1␣. of these inhibitors ( Figure 1H ). The result suggests that PI-3K/ Akt/mTOR pathway may attribute to the HER2-induced CXCR4
Cancer cell invasion involves a sequential series of critical steps, including adhesion to endothelial cells and migration toexpression.
ward chemotactic factors. To better understand which steps of HER2-induced invasion CXCR4 may contribute to, we examined CXCR4 is crucial for HER2-induced invasion, migration, and adhesion activities in vitro the migration and adhesion activities of HER2 stable transfectants and their parental cells in response to SDF-1␣ stimulation. Because HER2 induces CXCR4 expression, and both HER2 and interaction between CXCR4 and SDF-1␣ play an important role Migration was inhibited by a CXCR4-blocking antibody but not by the mouse IgG antibody ( Figure 2F ), indicating that CXCR4 in metastasis, we examined whether SDF-1␣/CXCR4 interaction contributes to HER2-driven invasive activities. Invasion assays is required for HER2-enhanced migration. The phenomenon was observed in 435/neo and 435/HER2 cells ( Figure 2F ) and in 3T3 were performed using the Boyden Chamber coated with Matrigel. It was clear that SDF-1␣ stimulated the in vitro invasive and 3T3/HER2 cells (data not shown). The adhesion assay, which measures adherence to cultured endothelial cells, also indicated activity in 435/HER2 cells but not in the 435/neo control cells. Moreover, the SDF-1␣-induced invasive activity was inhibited that the CXCR4-blocking antibody inhibited HER2-induced adhesion activity in BT-474 and 3T3/HER2 cells (Figures 2G and 2H) . in a concentration-dependent manner by a CXCR4-blocking antibody (Figures 2A and 2B ), but not by a control IgG antibody.
Taken together, these results demonstrate that HER2-induced CXCR4 expression plays a critical role in increasing the migra-CXCR4 was cotransfected with HA-tagged ubiquitin and either active HER2 or kinase-dead HER2 into HEK293 cells; CXCR4 tion of cancer cells and their adhesion to endothelial cells in responding to SDF-1␣ stimulation. Since SDF-1␣ is highly exwas then immunoprecipitated, and the precipitate was immunoblotted with anti-HA antibody to detect HA-ubiquitin. The pressed in metastatic organs such as lung, liver, and bone, this finding provides in vitro support for a plausible mechanism for level of the ubiquitinated receptor was significantly lower in the lysate from active HER2 transfection than that from kinase-dead HER2-enhanced metastasis and homing to metastatic organs (please see the in vivo study later).
form transfection ( Figure 3D ). This result further supported the idea that HER2 inhibits CXCR4 ubiquitination and that HER2 It should be mentioned that other mechanisms, in addition to increased CXCR4 expression, might contribute to SDFkinase activity is required for this action. Recently, it has been shown that the Nedd4-like E3 ubiquitin ligase AIP4 mediates 1␣-enhanced adhesion activity. We have previously shown that the basal level of adhesion activity in MDA-MB-435 is not inagonist-promoted ubiquitination of CXCR4 . To further investigate whether AIP4 might be involved in creased by enforcing HER2 expression in the 435/HER2 cells (Tan et al., 1997) . Consistent with this notion, we noticed that HER2-mediated CXCR4 upregulation, we cotransfected HAtagged CXCR4, HER2, and either AIP4 or its catalytically inactive SDF-1␣ did not stimulate adhesion activity in both 435 and 435/ HER2 cells; accordingly, the CXCR4-blocking antibody did not mutant C830A at the ratio of 1:2:4, then measured CXCR4 expression using an anti-HA antibody ( Figure 3E ). As expected, affect the adhesion activity of 435/neo and 435/HER2 cells (data not shown). Thus, other mechanisms must be involved in en-HER2 enhanced CXCR4 expression (lanes 1 and 2), which was completely suppressed in the presence of AIP4 E3 ligase (lanes hancing the basal level of adhesion activity in MDA-MB-435 cells. Further investigation is required to determine whether 3 and 4). However, C830A did not suppress HER2-induced CXCR4 expression (lanes 5 and 6). These results indicated that this mechanism is through a CXCR4-independent pathway or downstream signaling of CXCR4.
AIP4 inhibits HER2-induced CXCR4 expression. Taken together, HER2 inhibits ligand-induced CXCR4 ubiquitination and then prevents CXCR4 from ligand-induced degradation. HER2 protects CXCR4 from ligand-induced protein degradation Although CXCR4 guides malignant cancer cells to metastatic CXCR4 is required for HER2-induced lung metastasis in vivo organs in which SDF-1␣ is enriched (Muller et al., 2001) , stimulation of SDF-1␣ can degrade CXCR4 (Marchese and Benovic, To gather further support for the idea that CXCR4 is required for HER2-induced in vitro invasion and to determine whether 2001). Therefore, we would expect that once the malignant cancer cells reached the SDF-1␣-enriched organs, partial CXCR4 CXCR4 is also required for HER2-induced metastasis in vivo, we designed a retroviral RNAi vector (pSR) to inhibit CXCR4 would be degraded, which would reduce the ability to contribute to other steps in metastasis, such as adhering to the endotheexpression (Brummelkamp et al., 2002) (Figure 4 ). The retrovirus expressing small interfering RNA (siRNA) against CXCR4 was lium and invading the basement membrane. However, the above results (Figures 2A-2H ) suggest that CXCR4 may have a role used to infect 435/HER2 transfectants, and the puromycineresistant stable colonies were pooled together and named in invasion, migration, and adhesion activity in the SDF-1␣-enriched organs. Thus, we investigated whether HER2 overex-435HER2/SR-iCXCR4. A similar control pool infected with the retrovirus containing an empty vector was selected and named pression might prevent CXCR4 from SDF-1␣-induced degradation. We examined the CXCR4 downregulation rate following 435HER2/SR-Ctrl. As expected, CXCR4 expression was reduced in the 435HER2/SR-iCXCR4 cells ( Figure 4A ), and their SDF-1␣ stimulation by FACS and found that the CXCR4 level quickly decreases; after about 1 hr of SDF-1␣ stimulation, the invasive activity was significantly decreased to a level comparable to that of the negative control 435/neo cells ( Figure 4B ). The CXCR4 level in MDA-MB-435 cells was 60% of that in untreated cells, consistent with a previous report (Marchese and Benovic, positive control 435HER2/SR-Ctrl cells maintained a high level of invasive activity ( Figure 4B ). Hence, the siRNA approach 2001). However, the CXCR4 level remained almost the same in the 435/HER2 cells after ligand stimulation for 1 hr ( Figure 3A) . further supports our findings that CXCR4 is required for HER2-induced invasive activity in responding to SDF-1␣ stimulation. We further used the pulse-chase assay to detect the degradation rate of CXCR4 following SDF-1␣ stimulation and found that
We next determined the in vivo metastatic potential of CXCR4 siRNA stable and control transfectants in 435/HER2 HER2 significantly lowers the ligand-induced protein degradation rate of CXCR4 ( Figure 3B ). The data indicated that HER2
and 435/neo cell lines by using the experimental metastasis assay. The mice were euthanized 120 days after injection with protects CXCR4 from ligand-induced downregulation. Thus, in HER2-overexpressing cancer cells, CXCR4 may not only play one of the above cell lines, and pulmonary and extrapulmonary metastases were examined. While the HER2 significantly ina role in homing to the metastatic organs, but also contribute to the invasive processes including enhanced migration and creased lung metastasis, as reported previously (Tan et al., 1997) , the number of metastatic lung nodules in the mice inadhesion activity in the SDF-1␣-enriched organs.
CXCR4 degradation correlates with its ubiquitination status jected with 435HER2/SR-iCXCR4 was significantly lower than that in the control mice (p Ͻ 0.01) ( Figures 4C and 4D ). In (Marchese and Benovic, 2001) , and ubiquitination of CXCR4 serves as a targeting signal for lysosomal degradation. To further addition, only two of the ten mice in the 435HER2/SR-iCXCR4 groups developed lung metastases, compared with eight of ten address the molecular mechanism of HER2 protection of CXCR4 from ligand-induced degradation, we next investigated the role mice in the control 435HER2/SR-Ctrl group (Table 1) . Both the size of the lung metastases and the total lung weight were of HER2 on ubiquitination of CXCR4. In the presence of SDF-1␣, HER2-expressing cells exhibit a reduced level of ubiquinated significantly lower in the 435HER2/SR-iCXCR4 group (Table 1 and Figure 4D ). All the metastatic tumors were confirmed by CXCR4 ( Figure 3C ), suggesting that HER2 inhibits CXCR4 monoubiquitination. To further support this notion, myc-tagged pathological examination (data not shown). Taken together, A: HER2 prevents SDF-1␣-induced downregulation of CXCR4. After cycloheximide treatment (30 min), SDF-1␣ was added, the endogenous expression of cell surface CXCR4 was analyzed by FACS at different time points, and the mean percentages of CXCR4 fluorescence were plotted. Representative FACS assay results are shown to compare CXCR4 expression before SDF-1␣ stimulation (green) and 1 hr poststimulation (red). B: Pulse-chase assay to measure the protein degradation rate under the SDF-1␣ stimulation: the means of the relative density were plotted in the bottom panel. All the experiments were repeated three times. C and D: HER2 inhibits SDF-1␣-induced ubiquitination of CXCR4. C: Serum-starved 435/neo and 435/HER2 cells were pretreated with the cycloheximide treatment for 30 min and then treated with SDF-1␣ for 1 hr, and the endogenous expression of cell surface CXCR4 was immunoprecipitated and blotted with monoclonal anti-ubiquitin antibody. D: HEK293 cells were transfected with Myc-tagged CXCR4 and HA-tagged ubiquitin plus either HER2 or kinasedead form K753M. Cells were incubated in the absence or presence of 100 nM SDF-1␣ for 1 hr at 37ЊC. Proteosome inhibitor MG 132 was added with SDF-1␣ serving as positive control. Receptors were immunoprecipitated, and membranes were blotted with an anti-HA antibody to detect the incorporation of epitope-tagged ubiquitin. Under these conditions, ubiquitinated receptor was slightly detectable in cells expressing HER2 but was increased and easily detected in cells expressing kinase-dead form K753M. Total cell lysates were also subjected to immunoblotting to detect the expression of CXCR4 and HER2. E: Effect of AIP4 and its catalytically inactive mutant C830A on HER2 mediated the upregulation of CXCR4. We cotransfected HA-tagged CXCR4, HER2, and either AIP4 or its catalytically inactive mutant C830A at the ratio of 1:2:4, then measured CXCR4 expression using an anti-HA antibody.
these results clearly show that the inhibition of CXCR4 by stable as CXCR4 high. We found a significantly positive correlation between HER2 and CXCR4 expression ( Figure 5A and Table siRNA reduces HER2-induced lung metastasis and that CXCR4 is required for HER2-mediated lung metastasis in vivo.
2). In human breast tumor tissues in which HER2 expression was positive, CXCR4 expression was also positive (case 1 in Figure 5A ), whereas in HER2-negative tumor tissues, CXCR4 CXCR4 is upregulated in HER2-overexpressed primary breast tumor tissues and is correlated expression was also undetectable (case 2 in Figure 5A ). It should be mentioned that the two images (top left and right, or bottom with poor patient survival To determine whether HER2-enhanced CXCR4 expression is left and right) were derived from nearby sections of the same tumor tissue. Among the 219 breast cancer tumor tissue samalso observed in primary tumor tissues, we performed immunohistochemical staining and scoring analysis (Camp et al., 1999;  ples that we examined, the correlation between HER2 and CXCR4 was statistically significant (p Ͻ 0.001; Table 2 ), support- Zhou et al., 2001) . Immunohistochemical scoring (H score) was determined by multiplying the staining intensity by the percenting the conclusion that overexpression of HER2 upregulates CXCR4 expression in vivo. Importantly, CXCR4 expression was age of positive tumor cells (Camp et al., 1999) . According to bimodal H score distribution, tissues with scores Ͻ130 were also found to be correlated with poor patient overall survival (p Ͻ 0.05) ( Figure 5B ). These results further support the idea designated as CXCR4 low, and scores Ͼ130 were designated 
C:
In vivo lung metastasis driven by HER2 is reduced by CXCR4 inhibition. The mice were euthanized 120 days after injection, and the number of lung metastasis nodules larger than 0.5 mm in diameter in each group was examined. *p Ͻ 0.05; **p Ͻ 0.01. D: A representative set of gross lungs with metastatic nodules.
that HER2 overexpression enhances CXCR4 expression and pression is a known marker of poor prognosis in breast cancer, our observations add strong clinical support for the identified indicate that CXCR4, like HER2 (Slamon et al., 1989) , also serves as a predictor for poor overall patient survival. mechanism, namely HER2 enhancement of CXCR4 expression. Cancer metastasis results from several highly organized sequential steps involving numerous interactions between the canDiscussion cer cells and host, but the detailed molecular mechanism is still not completely understood (Steeg, 2003 ; Yeatman and NicolThe RTK HER2 and the GPCR CXCR4 are two structurally unrelated receptors, but the current study demonstrates that HER2 son, 1993). CXCR4 is involved in breast cancer metastasis to specific organs (Liotta, 2001; Muller et al., 2001) ; however, the enhances CXCR4 expression and that CXCR4 is required for HER2-induced lung metastasis, therefore resolving a longstanddetailed mechanism of CXCR4 upregulation in malignant cancer remains poorly understood. Recently, CXCR4 was found to be ing puzzle of how HER2 overexpression guides cancer cells to home to their metastatic organs. CXCR4 expression was recently transactivated by hypoxia-induced factor-1␣ (HIF-1␣) at the transcriptional level in von Hippel-Lindau mutated renal cell carfound to be correlated with lymph node metastasis in a 79-case cohort of patients with invasive ductal carcinoma (Kato et al., cinoma (Bernards, 2003; Staller et al., 2003) , which serves as one plausible mechanism for CXCR4 upregulation. In the current 2003). In our 219-case breast cancer study, CXCR4 was further found to be associated with poorer patient survival, and a sigstudy, we identified two distinct mechanisms for CXCR4 upregulation by HER2 overexpression, enhancement of CXCR4 nificant correlation between HER2 and CXCR4 expression was also observed (p Ͻ 0.001). In view of the fact that HER2 overexprotein synthesis and inhibition of ligand-induced degradation. 2/10** 2.5 (0-3)** 0.8-1.0 3.0 Ϯ 0.7** 435neo/SR-Ctrl 3/7* 6.3 (0-8)* 0.5-4.0 3.1 Ϯ 0.6* 435neo/SR-iCXCR4 1/7 2 (0-2) 0.5-1.0 2.8 Ϯ 0.6
An experimental metastasis assay was used to determinate in vivo lung metastatic potential among MDA-MB-435cells, HER2 stable transfectants, and CXCR4 siRNA stable transfectants. The mice were euthanized 120 days after tail vein injection, and the frequency, number, and size of lung metastases and the whole lung weight were measured. Lung nodules Ͼ0.5 mm in diameter were counted. Student's t test was used to compare differences between each group. *Compared with the 435HER2/SR-Ctrl, p Ͻ 0.05. **Compared with the 435HER2/SR-Ctrl, p Ͻ 0.01. The 219 surgical specimens of breast tumor were stained with anti-HER2 and anti-CXCR4 antibody as shown in Figure 5 . Expression patterns in all samples are summarized here. The Pearson chi-square was used to analyze for significance of the relationship between CXCR4 expression and HER2 expression (p Ͻ 0.001).
kine and is expressed constitutively in some tissues, including bone marrow and lung, which are major homing organs for metastatic breast cancer (Muller et al., 2001; Nagasawa et al., 1996) . SDF-1␣ is present in serum at low concentrations, but in an inactive form (Villalba et al., 2003) . Thus, serum SDF-1␣ may not affect homing of CXCR4-expressing cancer cells. In addition to attracting CXCR4-expressing malignant cancer cells to certain organs (Muller et al., 2001) , SDF-1␣ can also induce CXCR4 degradation (Marchese and Benovic, 2001 ). This raises the interesting question of whether CXCR4 could be involved in multiple-step metastatic processes, such as invasion through the basement membrane and adherence to endothelial cells, which are critical in the extravasation process for cancer cells to leave the circulation and migrate into normal organs. Our results ( Figure 2 ) clearly indicate that CXCR4 is required for invasion, migration, and adhesion activities under SDF-1␣-stimulated condi- gests that CXCR4 not only plays a role in homing to the meta-
Kaplan-Meier analysis of overall survival in patients with breast cancer static organs, but also contributes to invasive processes, such carcinoma according to their CXCR4 expression levels (p Ͻ 0.05).
as enhanced migration and adhesion activity, in SDF-1␣-enriched organs for HER2-overexpressing cancer cells. It is not yet clear whether malignant cancer cells in which HER2 is not overexpressed acquire a similar mechanism to prevent CXCR4 degraPresently, the detailed molecular mechanisms for receptor endation by SDF-1␣ or if they activate other mechanisms to condocytosis, endosome sorting, and degradation of GPCRs, intribute to invasion and adhesion activities in the extravasation cluding CXCR4, are not completely understood (Shenoy et al., process. The MDA-MB-435 metastatic breast cancer cell line, 2001). Recently, it has been suggested that the mechanisms which does not overexpress HER2, has acquired a strong adheinvolved in CXCR4 ubiquitination and sorting may share some sion activity through other mechanisms, as HER2 does not encommon features with EGFR endocytosis and degradation prohance its ability to adhere to endothelial cells (Tan et al., 1997 ) cesses, although they are structurally unrelated membrane reand a CXCR4-blocking antibody does not affect its adhesion ceptors (Hendriks et al., 2003; Lloyd et al., 2002; Marchese activity (data not shown). et al., 2003; Polo et al., 2002; Worthylake et al., 1999) . One
In summary, HER2 upregulates the expression of CXCR4, mechanism to degrade CXCR4 is internalization of CXCR4 which is required for HER2-enhanced invasion, migration, adhethrough early endosomes, and then sorting into late endosomes sion, and metastasis to the lung. CXCR4 expression is correand lysosomes. HER2 may inhibit CXCR4 ubiquitination and lated with overall patient survival in breast cancer. Similar to abrogate subsequent sorting steps and therefore prevent its HER2, this observation will have important clinical implications. degradation. Taken together, CXCR4 expression can be regu-
The study of linkage between these two structurally unrelated lated through different mechanisms. It would be interesting to membrane receptors, HER2 and CXCR4, both of which play explore when and where each mechanism is used to regulate critical roles in cancer metastasis, has advanced our knowledge CXCR4 expression.
The CXCR4 ligand SDF-1␣ is a locally secreted small cytoof how HER2-overexpressing cancer cells home to their meta-incubating the cells with 100 ng/ml SDF-1␣ for 1 hr at 37ЊC. Cell-to-cell static organs. It may also help us to better understand molecular adhesion then proceeded for 30 min at 37ЊC. OD was measured at 490 nm.
mechanisms of cancer metastasis.
Retroviral siRNA stable cell lines Experimental procedures
Retroviral siRNA vector (pSUPER.RETRO) was purchased from OligoEngine (Seattle, WA) (Brummelkamp et al., 2002) . The CXCR4 RNAi primers were Cell lines, DNA constructs, and antibodies 5Ј-GATCCCCTGGATTGGTCATCCTGGTCTTCAAGAGAGACCAGGATGAC All cell lines were grown in Dulbecco's modified Eagle's medium (DMEM)/ CAATCCATTTTTGGAAA-3Ј and 5Ј-AGCTTTTCCAAAAATGGATTGGTCATC F12 supplemented with 10% fetal bovine serum. Cell line NIH3T3 subtype CTGGTCTCTCTTGAAGACCAGGATGACCAATCCAGGG. Control primers and its HER2 stable transfectant and human breast cancer cell line MDAwere 5Ј-GATCCCCTTTTTGGAAA-3Ј and 5Ј-AGCTTTTCCAAAAAGGG-3Ј. MB-435 and its two HER2 stable transfectants have been described pre-
The retrovirus was produced using the Phoenix Retroviral System (Orbigen, viously (Tan et al., 1997 (Tan et al., , 2002 Zhou et al., 2001) .
San Diego, CA). Cells were infected with retroviral supernatant and selected HA-CXCR4 and FLAG-ubiquitin constructs were kindly provided by Dr. Bein puromycine medium. CXCR4 expression was confirmed by FACS. novic ; wild-type and catalytically inactive AIP4 plasmids were kindly provided by Dr. Tony Pawson. The anti-myc and anti-HA Experimental metastasis assay polyclonal antibodies were purchased from Sigma-Aldrich. siRNA directed Eight-week-old female nude mice (Charles River, Wilmington, MA) were used against human HER2 was from Dharmacon Research. in the experimental metastasis assay described previously (Tan et al., 1997) . antibodies (MAB170, MAB172) were from R&D systems. Other CXCR4 antiThe mice were euthanized 120 days after the injection of cancer cells. The bodies were from Abcam and Lab Vision/Neomarkers. The monoclonal antianimal experiments were approved and in compliance with the institution's ubiquitin antibody (6C1) was from Sigma.
guidelines.
Immunoprecipitation and Western blotting
Immunoprecipitation and Western blotting were performed as described
Immunohistochemical staining and analysis previously (Li et al., 2003) , with 1 g of antibody against CXCR4 or normal Human breast cancer tissue samples were collected and stained, as decontrol IgG in 1.0 mg whole lysate protein.
scribed before (Deng et al., 2002; Zhou et al., 2001 ) with anti-human CXCR4 monoclonal Ab (MAB170; 1:400 dilution) and anti-human HER2 Ab (DAKO; FACS and immunofluorescent staining 1:100). CXCR4 positivity was assessed semiquantitatively using staining For FACS analysis, cells were treated with mouse anti-CXCR4 antibody intensity and percentage by two independent pathological investigators. H (MAB172; R&D systems, Minneapolis, MN) or normal IgG overnight at 4ЊC score was determined by multiplying the staining intensity by the percentage and then stained with FITC-conjugated IgG at room temperature for 30 min of positive tumor cells (Camp et al., 1999) . Chi-square analysis was used to and analyzed with a Becton Dickinson flow cytometer (Franklin Lakes, NJ) .
analyze the relationship between CXCR4 and HER2 expression. The KaplanFor the ligand-induced receptor degradation, serum-starved cells were pre-
Meier method was used to analyze breast cancer patient overall survival. treated with 20 g/ml cycloheximide for 30 min, and then SDF-1␣ (R&D Statistical significance was defined as p Ͻ 0.05. Systems) was added to the final concentration of 100 ng/ml for 1 to 4 hr. Immunofluorescent staining was performed as described previously (Zhou Acknowledgments et al., 2001) . with microscopy setup and image processing; Jean Wang for statistical [ 35 S]Met-Cys was added to a final concentration of 0.3 mCi/ml, and the cells assistance; Dr. Chin-Hsing Chen for performing mice tail vein injections; and were pulse labeled for 1, 2, 4, and 8 hr and then harvested. Protein degradaChu-Li Weng for preparing animal tissue. tion was measured by pulse-chase assay: the cells were rinsed after 2 hr pulse labeling, incubated in medium containing nonradioactive Met-Cys and 20 g/ml cycloheximide for 1, 2, 4, and 8 hr, and then harvested. Immunoprecipitation and SDS-PAGE were then performed as described previously (Li Received: December 22, 2003 . Cell invasion was examined as described before with modification (Tan et al., 1997) . SDF-1␣ (600 l; 100 ng/ml) was added to the lower chamber, References and 1-10 g/ml CXCR4 blocking antibody (MAB170/12G5; R&D Systems) or 5-15 g/ml Herceptin (Genotech, CA) was added to the top chamber to Bernards, R. (2003) . Cancer: cues for migration. Nature 425, 247-248. block the CXCR4 receptor binding. Invading cells were stained using DAPI and counted under fluorescence microscopy at medium-power fields (200ϫ Brummelkamp, T.R., Bernards, R., and Agami, R. (2002) . Stable suppression or 100ϫ). Cell migration was assayed using a similar approach without of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247. Matrigel coating; 3 ϫ 10 4 cells were added to the upper chamber and Camp, R.L., Rimm, E.B., and Rimm, D.L. (1999) . Met expression is associated incubated from 6 hr to overnight.
with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86, 2259-2265.
Adhesion assay
The cells were labeled with 3Ј-O-acetyl-2Ј,7Ј-bis(carboxyethyl)-4-5-carboxyCarter, P., Presta, L., Gorman, C.M., Ridgway, J.B., Henner, D., Wong, fluorescein ester for 30 min. Labeled cells (3 ϫ 10 4 ) were deposited onto W.L., Rowland, A.M., Kotts, C., Carver, M.E., and Shepard, H.M. (1992) . human umbilical vein endothelial cells or simian virus-40 transformated muHumanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89, 4285-4289. rine lymphoid endothelial cell monolayer. Pretreatment was performed by
